Page last updated: 2024-08-24

topotecan and Small Cell Lung Carcinoma

topotecan has been researched along with Small Cell Lung Carcinoma in 82 studies

Research

Studies (82)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (13.41)	29.6817
2010's	56 (68.29)	24.3611
2020's	15 (18.29)	2.80

Authors

Authors	Studies
Dai, X; Jiang, T; Li, J; Qi, X; Wu, G; Yin, R; Yu, R; Zhang, G	1
Fang, Z; He, M; Liu, M; Liu, Q; Peng, J; Wei, Y; Wu, B; Yi, F; Zhang, W	1
Cao, GZ; Hua, JH; Lin, WC; Lv, XT; Ma, LY; Yin, YP	1
Pommier, Y; Schultz, CW; Sun, Y; Thomas, A; Zhang, Y	1
Weber, JP; Wermke, M	1
Adeyemi, A; Boccuti, A; Caisip, C; Hanvesakul, R; Jansen, JP; Naveh, N; Park, JE; Rengarajan, B; Wilson, FR	1
Aljumaily, R; Burris Iii, HA; Johnson, ML; Jones, SF; Patel, MR; Spigel, DR	1
Gerner-Rasmussen, J; Hansen, O; Holm, B; Jeppesen, N; Langer, SW; Mau-Sørensen, M; McCulloch, T; Nielsen, HA; Nyhus, CH; Rytter, C; Wedervang, K	1
Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS	1
Besse, B; Blackhall, F; Califano, R; Cappuzzo, F; de Marinis, F; De Ruysscher, D; Felip, E; Früh, M; Garrido, P; Novello, S; O'Brien, M; Panje, CM; Paz Ares, L; Putora, PM; Reck, M; Westeel, V	1
Basse, C; El Kaddissi, A	1
Chen, H; Horita, N; Takeshi, K	1
Blackhall, F; Caffrey, L; Cappuzzo, F; Cetnar, J; Cho, BC; Erman, M; Greillier, L; Groen, H; Hansen, K; Jao, K; Kato, T; Komarnitsky, P; Langer, SW; Luo, Y; Majem, M; Nackaerts, K; Okamoto, I; Penkov, K; Reguart, N; Reinmuth, N; Schuette, W; Sun, Z; Syrigos, K; Tanwani, P	1
Andric, Z; Antal, JM; Daniel, D; Dragnev, KH; Goldschmidt, J; Gwaltney, C; Morris, SR; Pritchett, Y; Skaltsa, K; Weiss, J	1
Elloumi, F; Jo, U; Kim, SH; Murai, Y; Pommier, Y; Rajapakse, VN; Saha, LK; Schultz, CW; Senatorov, IS; Takahashi, N; Thomas, A; Zenke, FT; Zimmermann, A	1
Bunn, PA; Chan, DC; Drummond, DC; Fitzgerald, JB; Gaddy, DF; Hendriks, BS; Kalra, AV; Klinz, SG; Lee, H; Leonard, SC; Paz, N	1
Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K	1
An, T; Bai, H; Chen, H; Duan, J; Liu, X; Lv, C; Wang, J; Wang, Y; Wang, Z; Wu, M; Yang, X; Zhao, J; Zheng, Q; Zhong, J; Zhuo, M	1
Imai, H; Kaburagi, T; Kaira, K; Kanazawa, K; Kasai, T; Kotake, M; Minato, K; Minemura, H; Nakamura, Y; Shibata, Y; Sugiyama, T; Yamada, Y	1
Drapkin, BJ; Farago, AF; Galmarini, CM; Kahatt, C; Lopez-Vilarino de Ramos, JA; Núñez, R; Paz-Ares, L	1
Beaumont, H; Chadjaa, M; Evans, TL; Guermazi, A; Hong, SR; Klifa, C; Monostori, Z	1
Nazha, B; Owonikoko, TK	1
Lin, B; Shao, L; Song, Z; Zhang, Y	1
Agelaki, S; Bompolaki, I; Chandrinos, V; Georgoulias, V; Kalbakis, K; Kontopodis, E; Kotsakis, A; Papadimitraki, E; Stoltidis, D; Zafeiriou, Z	1
Cao, B; Chen, XJ; Ge, XH; Li, ZG; Lin, Q; Liu, ML; Liu, YE; Ren, XC; Wang, DY; Wang, YQ	1
Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV	1
Hamilton, G; Klameth, L; Rath, B; Thalhammer, T	1
Ardizzoni, A; Boni, L; Tiseo, M	1
Allen, JW; Gadgeel, SM; Gandara, DR; Jahanzeb, M; Kelly, K; Mack, PC; Mohamed, MK; Moon, J; Redman, M; Saba, HM	1
Ardizzoni, A; Boni, L; Buti, S; Mattioni, R; Tiseo, M	1
Ausch, C; Bajna, E; Brenner, S; Buxhofer-Ausch, V; Hamilton, G; Jäger, W; Klameth, L; Reiner, A; Riha, J; Schölm, M; Thalhammer, T	1
Bosquée, L; Bubis, J; Clingan, P; Domine, M; Jotte, R; Li, S; Lorigan, P; Mezger, J; Nackaerts, K; O'Brien, ME; Reck, M; Renschler, MF; Schütte, W; Shepherd, FA; Socinski, MA; Spigel, DR; Steins, M; Trigo, JM; von Pawel, J	1
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ	1
Bongiovanni, A; Burgio, MA; Califano, R; Carloni, F; Casanova, C; Cavallo, G; Di Battista, M; Genestreti, G; Kazushige, W; Kenmotsu, H; Korkmaz, T; Metro, G; Roopa, K; Scarpi, E; Selcuk, S; Tiseo, M	1
Bianco, V; Francini, E; Ghiribelli, C; Laera, L; Luzzi, L; Martellucci, I; Paladini, P; Petrioli, R; Roviello, G; Voltolini, L	1
Enomoto, Y; Hasegawa, H; Imokawa, S; Inui, N; Karayama, M; Matsui, T; Ozawa, Y; Suda, T; Yokomura, K	1
Chadjaa, M; Cho, BC; Evans, TL; Fischer, JR; Martinez, P; Ramlau, R; Shen, L; Shepherd, FA; Syrigos, KN; Udud, K; Wolf, M	1
Horita, N; Inoue, M; Kaneko, T; Kudo, M; Nagai, K; Nagakura, H; Nakashima, K; Sato, T; Shibata, Y; Shinkai, M; Tashiro, K; Tsukahara, T; Ushio, R; Watanabe, H; Yamamoto, M	1
Fujimoto, D; Ito, J; Katakami, N; Kato, R; Kogo, M; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Sato, Y; Shimizu, R; Teraoka, S; Tomii, K	1
Horita, N; Ikeda, M; Kaneko, T; Kobayashi, N; Kudo, M; Nagai, K; Nagakura, H; Nakashima, K; Sato, T; Shibata, Y; Shinkai, M; Tashiro, K; Tsukahara, T; Ushio, R; Watanabe, H; Yamamoto, M	1
Casaluce, F; Gridelli, C; Maione, P; Palazzolo, G; Rossi, A; Sacco, PC; Santabarbara, G; Sgambato, A	1
Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N	1
Bessho, A; Fujimoto, N; Fujiwara, K; Harita, S; Hosokawa, S; Hotta, K; Kamei, H; Kanazawa, S; Kiura, K; Kozuki, T; Kubo, T; Kuyama, S; Maeda, T; Ninomiya, K; Ninomiya, T; Okada, T; Tabata, M; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H	1
Benedetti, F; Cortinovis, D; Galetta, D; Inoue, A; Kubota, K; Makris, L; Niho, S; Nishio, M; Satouchi, M; Scagliotti, G; Valmadre, G; Yoshihara, E	1
Horie, M; Nagase, T; Ohshima, M; Saito, A; Suzuki, HI	1
Alistar, A; Bonomi, M; Chan, MD; Isom, S; Lamar, ZS; Lycan, TW; Miller, AA; Pardee, TS; Petty, WJ; Ruiz, J	1
Jensen, BB; Jensen, PB; Jeppesen, N; Langer, SW; Lassen, U; Mellemgaard, A; Rytter, C; Sorensen, M; Østerlind, K	1
Friedrichs, N; Gorschlüter, M; Gressner, O; Mey, U; Popp, H; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J	1
Antras, L; Chen, L; Duh, MS; Neary, M; O'Brien, ME	1
Fietkau, R; Grabenbauer, GG; Hedde, JP; Ko, Y; Kocher, M; Muller, RP; Neuhaus, T; Schueller, H; Stier, S	1
Hann, CL; Rudin, CM	1
Guo, C; Guo, QS; Liu, XJ; Liu, YL; Song, XR; Zhang, Q	1
Kakavelas, P; Kontakiotis, T; Lithoxopoulou, H; Mylonaki, E; Rapti, E; Tsiouda, T; Zarogoulidis, K; Zarogoulidis, P; Zarogoulidou, V	1
Fukuoka, M; Kashii, T; Kobayashi, M; Kurata, T; Nakagawa, K; Satoh, T; Seki, N; Takeda, K; Tsuboi, M	1
Araújo, AM; Bravo, EM; Coelho, AL; Faria, AL; Rocha, IM; Rocha, MA	1
Fennell, DA; Hurwitz, JL; McCoy, F; Scullin, P	1
Arvelo, F; Assayag, F; Bourgeois, Y; Daniel, C; Decaudin, D; Froget, B; Legrier, ME; Livartowski, A; Némati, F; Poupon, MF	1
Bruzzese, F; Budillon, A; Castelli, S; Desideri, A; Di Gennaro, E; Rocco, M	1
Anagnostopoulos, A; Antoniou, D; Ardavanis, A; Athanasiadis, A; Koutantos, J; Papadopoulos, G; Papakotoulas, P; Pectasides, D; Stathopoulos, GP; Trafalis, D; Vaslamatzis, M	1
Bird, A; Clegg, A; Harris, P; Hartwell, D; Jones, J; Loveman, E; Welch, K	1
Berzinec, P; Brincat, S; Kasan, P; Ostoros, G; Pesek, M; Pirker, R; Plāte, S; Purkalne, G; Rooneem, R; Skricková, J; Stanculeanu, D; Timcheva, C; Tzekova, V; Zakotnik, B; Zielinski, CC; Zwitter, M	1
Jiang, W; Lin, L; Xu, G; Xue, C; Zhang, L; Zhang, Y; Zhao, H; Zhao, Y	1
Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Baka, S; Georgoulias, V; Gerogianni, A; Kalbakis, K; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Pavlakou, G; Tsaroucha, E; Vamvakas, L; Veslemes, M	1
Bird, A; Clegg, A; Harris, P; Hartwell, D; Jones, J; Loveman, E	1
Bashir, Z; Gooch, CL; Kleijnen, J; Riemsma, R; Simons, JP	1
Brainerd, V; Chinnasami, B; Fain, J; Fidias, P; Heist, RS; Khan, W; Leopold, L; Lynch, TJ; Molina, JR; Sequist, LV; Temel, JS	1
Ando, M; Ichinose, Y; Kiura, K; Nishiwaki, Y; Sakai, H; Segawa, Y; Seto, T; Watanabe, K; Yokoyama, A	1
Aglione, S; Bareggi, C; Blackhall, F; Califano, R; Collovà, E; Farina, G; Fatigoni, S; Galetta, D; Gallerani, E; Garassino, MC; Ghidini, A; La Verde, N; Lo Dico, M; Lorigan, P; Mancuso, A; Martelli, O; Michetti, G; Rossi, A; Saggia, C; Thatcher, N; Torri, V	1
Conkling, P; Fitzgibbons, JF; Galsky, MD; Jotte, R; Klein, L; McNally, R; Oliver, JW; Renschler, MF; Reynolds, C	1
Chikamori, K; Harita, S; Hosokawa, S; Hotta, K; Kishino, D; Kiura, K; Kuyama, S; Nogami, N; Shibayama, T; Shinkai, T; Tabata, M; Takigawa, N; Tamaoki, A; Tanimoto, M; Ueoka, H	1
Ando, M; Eguchi, K; Hosomi, Y; Ichinose, Y; Kiura, K; Kudo, S; Masuda, N; Matsui, K; Niho, S; Sakai, H; Shibuya, M; Takeda, K; Watanabe, K	1
Higashiguchi, M; Hirashima, T; Kawase, I; Kobayashi, M; Matsuura, Y; Morishita, N; Okamoto, N; Sasada, S; Suzuki, H; Tamiya, M; Tsumori, T; Uehara, N	1
Alizon, C; Hureaux, J; Urban, T	1
Maxwell, PJ; Pineda, D	1
Cardona, AF; Reveiz, L; Rueda, JR	1
Acker, T; Banik, N; Bogenrieder, T; Eberhardt, F; Eschbach, C; Fink, TH; Heigener, DF; Huber, RM; Hummler, S; Ittel, T; Schroeder, M; Schweisfurth, H; Steinhauer, EU; Virchow, JC; Waller, C; Wolf, M	1
Alici, S; Altinbas, M; Arpaci, E; Camci, C; Gumus, M; Kalender, ME; Kaplan, MA; Karaca, H; Oven, B; Sevinc, A; Uncu, D; Yildiz, R	1
Spigel, DR	1
Du, P; Gui, L; Han, X; Li, N; Shi, Y; Song, Y; Yang, J	1
Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N	1
Bhatt, K; Lane, S; Legenne, P; Spigel, DR; Waterhouse, DM	1
Bogart, JA; Green, MR; Herndon, JE; Lee, ME; Lyss, AP; Miller, AA; Turrisi, AT; Watson, D	1

Reviews

13 review(s) available for topotecan and Small Cell Lung Carcinoma

Article	Year
Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Chemotherapy, 2021, Volume: 66, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Coordination Complexes; Etoposide; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome	2021
[Small cell lung cancer-Established standards and new approaches]. Innere Medizin (Heidelberg, Germany), 2022, Volume: 63, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Topotecan	2022
Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer. Journal of comparative effectiveness research, 2023, Volume: 12, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan	2023
Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients. Scientific reports, 2015, Oct-21, Volume: 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan	2015
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. Scientific reports, 2016, Jan-11, Volume: 6 Topics: Anthracyclines; Antineoplastic Agents; Asian People; Humans; Japan; Lung Neoplasms; Neutropenia; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome; White People	2016
Optimal drugs for second-line treatment of patients with small-cell lung cancer. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:7 Topics: Anthracyclines; Antibodies, Monoclonal; Antineoplastic Agents; Humans; Immunotherapy; Ipilimumab; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan	2016
Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park, N.Y.), 2008, Nov-30, Volume: 22, Issue:13 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome	2008
New advances in the second-line treatment of small cell lung cancer. The oncologist, 2009, Volume: 14, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-bcl-2; Quality of Life; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2009
The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:19 Topics: Adult; Antineoplastic Agents; Cost-Benefit Analysis; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Topotecan	2010
Therapy of small cell lung cancer with emphasis on oral topotecan. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 70, Issue:1 Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan	2010
Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer treatment reviews, 2011, Volume: 37, Issue:3 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan	2011
Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC cancer, 2010, Aug-17, Volume: 10 Topics: Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topoisomerase Inhibitors; Topotecan	2010
Chemotherapy for brain metastases from small cell lung cancer. The Cochrane database of systematic reviews, 2012, Jun-13, Issue:6 Topics: Antineoplastic Agents; Brain Neoplasms; Cisplatin; Cranial Irradiation; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Teniposide; Topotecan	2012

Trials

32 trial(s) available for topotecan and Small Cell Lung Carcinoma

Article	Year
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies. The oncologist, 2023, 07-05, Volume: 28, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Genital Neoplasms, Female; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan	2023
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan. Acta oncologica (Stockholm, Sweden), 2023, Volume: 62, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Topotecan	2023
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021, Volume: 16, Issue:9 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Humans; Immunoconjugates; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Middle Aged; Small Cell Lung Carcinoma; Topotecan	2021
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018, Volume: 20, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2018
ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future oncology (London, England), 2019, Volume: 15, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carbolines; Cyclophosphamide; Doxorubicin; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Platinum; Progression-Free Survival; Small Cell Lung Carcinoma; Topotecan; Tumor Microenvironment; Vincristine	2019
Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection. Cancer imaging : the official publication of the International Cancer Imaging Society, 2018, Dec-11, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Factors; Small Cell Lung Carcinoma; Taxoids; Topotecan; Tumor Burden	2018
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Palliative Care; Small Cell Lung Carcinoma; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan	2013
Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer. Radiation oncology (London, England), 2013, Oct-14, Volume: 8 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Radiotherapy, Conformal; Small Cell Lung Carcinoma; Topotecan	2013
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	2014
Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Aug-10, Volume: 32, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Small Cell Lung Carcinoma; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Dec-10, Volume: 32, Issue:35 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Disease-Free Survival; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone); Odds Ratio; Polymorphism, Single Nucleotide; Proportional Hazards Models; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome; Young Adult	2014
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult	2015
Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Response Evaluation Criteria in Solid Tumors; Retreatment; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan	2015
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2016
A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Endpoint Determination; Female; Humans; Lung Neoplasms; Male; Radiotherapy; Small Cell Lung Carcinoma; Survival Analysis; Topotecan	2016
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy. Lung cancer (Amsterdam, Netherlands), 2016, Volume: 100 Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Platinum; Pyrrolidines; Small Cell Lung Carcinoma; Thymine; Topotecan; Treatment Outcome; Trifluridine; Uracil	2016
A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PloS one, 2016, Volume: 11, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Cell Line, Tumor; Female; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Sulfides; Topoisomerase I Inhibitors; Topotecan	2016
Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2008
A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. British journal of cancer, 2009, Jan-27, Volume: 100, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Quality of Life; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2009
A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Young Adult	2009
Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study. Anti-cancer drugs, 2010, Volume: 21, Issue:2 Topics: Administration, Oral; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia; Time Factors; Topotecan; Treatment Outcome	2010
Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. Anticancer research, 2010, Volume: 30, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2010
Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Resistance, Neoplasm; Female; Gossypol; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2010
Phase I study of topotecan and cisplatin in patients with small cell lung cancer. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Small Cell Lung Carcinoma; Topotecan	2011
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 72, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome	2011
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-20, Volume: 29, Issue:3 Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma; Survival Analysis; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan; United States	2011
A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:1 Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome	2011
Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer research, 2011, Volume: 31, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome; Young Adult	2011
Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Small Cell Lung Carcinoma; Topotecan	2012
Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS. Journal of pharmaceutical and biomedical analysis, 2013, Mar-25, Volume: 76 Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; China; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Limit of Detection; Lung Neoplasms; Male; Reproducibility of Results; Small Cell Lung Carcinoma; Tandem Mass Spectrometry; Topoisomerase I Inhibitors; Topotecan	2013
Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Clinical lung cancer, 2013, Volume: 14, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2013
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. International journal of radiation oncology, biology, physics, 2004, Jun-01, Volume: 59, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Small Cell Lung Carcinoma; Survival Analysis; Topotecan	2004

Other Studies

37 other study(ies) available for topotecan and Small Cell Lung Carcinoma

Article	Year
Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo. European journal of medicinal chemistry, 2022, Nov-05, Volume: 241 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Lung Neoplasms; Small Cell Lung Carcinoma	2022
FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11. Acta pharmacologica Sinica, 2022, Volume: 43, Issue:8 Topics: Cell Line, Tumor; Depsipeptides; DNA Methylation; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Nuclear Proteins; Small Cell Lung Carcinoma; Topotecan	2022
CDK7 Inhibition Synergizes with Topoisomerase I Inhibition in Small Cell Lung Cancer Cells by Inducing Ubiquitin-Mediated Proteolysis of RNA Polymerase II. Molecular cancer therapeutics, 2022, 09-06, Volume: 21, Issue:9 Topics: Antineoplastic Agents; Cell Line, Tumor; Cyclin-Dependent Kinases; DNA Topoisomerases, Type I; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proteolysis; RNA Polymerase II; Small Cell Lung Carcinoma; Topotecan; Ubiquitin	2022
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer. European journal of cancer care, 2020, Volume: 29, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2020
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung cancer (Amsterdam, Netherlands), 2020, Volume: 146 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan	2020
[New European approvals: Durvalumab - In first line metastatic small-cell lung cancer]. Bulletin du cancer, 2020, Volume: 107, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Immunotherapy; Lung Neoplasms; Nivolumab; Small Cell Lung Carcinoma; Topotecan	2020
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer. The Lancet. Oncology, 2020, Volume: 21, Issue:12 Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan	2020
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clinical lung cancer, 2021, Volume: 22, Issue:5 Topics: Antineoplastic Agents; Bone Marrow; Clinical Trials, Phase II as Topic; Double-Blind Method; Humans; Patient Reported Outcome Measures; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan	2021
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents. Molecular cancer therapeutics, 2021, Volume: 20, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Deoxycytidine; DNA Replication; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Isoxazoles; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Pyrazines; Pyrazoles; Small Cell Lung Carcinoma; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2021
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anti-cancer drugs, 2017, Volume: 28, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Random Allocation; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays	2017
Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. Thoracic cancer, 2018, Volume: 9, Issue:9 Topics: Aged; Biomarkers, Tumor; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Recurrence; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Topoisomerase I Inhibitors; Topotecan	2018
Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. Thoracic cancer, 2018, Volume: 9, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Recurrence; Retreatment; Retrospective Studies; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2018
The clinical conundrum of managing relapsed small cell lung cancer. Cancer, 2019, 04-01, Volume: 125, Issue:7 Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan	2019
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan	2013
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. Molecules (Basel, Switzerland), 2014, Feb-17, Volume: 19, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Small Cell Lung Carcinoma; Topotecan	2014
Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:13 Topics: Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Small Cell Lung Carcinoma; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	2014
Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:1 Topics: Aged; Antineoplastic Agents; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2014
Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy. Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Chromogranins; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lung; Lung Neoplasms; Organic Anion Transporters; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Synaptophysin; Topotecan; Tumor Cells, Cultured	2015
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. Clinical lung cancer, 2015, Volume: 16, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum Compounds; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome	2015
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience. Clinical lung cancer, 2015, Volume: 16, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Etoposide; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Neutropenia; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome	2015
Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:3 Topics: Aged; Aged, 80 and over; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan	2015
Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease. Anticancer research, 2015, Volume: 35, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2015
YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer. Cancer science, 2016, Volume: 107, Issue:12 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Lung Neoplasms; Phenotype; Phosphoproteins; Small Cell Lung Carcinoma; Topotecan; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Transcriptome; YAP-Signaling Proteins	2016
Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation. Onkologie, 2008, Volume: 31, Issue:8-9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome	2008
Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Palliative Care; Randomized Controlled Trials as Topic; Self-Assessment; Severity of Illness Index; Sickness Impact Profile; Small Cell Lung Carcinoma; Surveys and Questionnaires; Topotecan	2008
[Down-regulation of TopI by RNA interference reduces the drug-sensitivity of small cell lung cancer cell lines to topotecan]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:10 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Down-Regulation; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Small Cell Lung Carcinoma; Topotecan; Transfection	2008
Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2009, Volume: 66, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Tolerance; Etoposide; Female; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome	2009
Topotecan in second-line treatment of small-cell lung cancer--how it works in our daily clinical practice? Current drug safety, 2010, Volume: 5, Issue:2 Topics: Adult; Aged; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2010
Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts. Anti-cancer drugs, 2010, Volume: 21, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Humans; Ifosfamide; Lung Neoplasms; Mice; Mice, Nude; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome; Xenograft Model Antitumor Assays	2010
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Molecular cancer therapeutics, 2009, Volume: 8, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Drug Synergism; Histone Deacetylases; Humans; Hydroxamic Acids; Lung Neoplasms; Reactive Oxygen Species; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Vorinostat	2009
[Immediate versus delayed topotecan after first-line therapy in small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2010, Volume: 13, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome	2010
Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease. Journal of chemotherapy (Florence, Italy), 2011, Volume: 23, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Topotecan	2011
[Postmarketing surveillance study on the use of topotecan in small-cell lung cancer. Use of topotecan in a pneumology university department]. Revue des maladies respiratoires, 2012, Volume: 29, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hospital Departments; Hospitals, University; Humans; Lung Neoplasms; Male; Middle Aged; Product Surveillance, Postmarketing; Pulmonary Medicine; Small Cell Lung Carcinoma; Topotecan; Young Adult	2012
Small cell lung cancer metastasizing to the colon in a colovesicular fistula in the setting of diverticulitis. The American surgeon, 2012, Volume: 78, Issue:5 Topics: Aged, 80 and over; Biopsy, Needle; Colectomy; Colostomy; Combined Modality Therapy; Diverticulitis, Colonic; Female; Follow-Up Studies; Humans; Immunohistochemistry; Intestinal Fistula; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiotherapy Dosage; Risk Assessment; Sigmoid Neoplasms; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Topotecan; Treatment Outcome; Urinary Bladder Fistula	2012
Weekly topotecan for recurrent small cell lung cancer - a retrospective Anatolian Medical Oncology Group study. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:6 Topics: Adult; Aged; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2012
Treatment update in small-cell lung cancer: from limited to extensive disease. Current treatment options in oncology, 2012, Volume: 13, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Topotecan	2012
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. American journal of clinical oncology, 2015, Volume: 38, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome	2015